GlassScriptPhysician profile
Melissa R Isbell
NPI 1881660660
$10,851.51
in general payments reported to CMS, 2019-2025
44 companies · $1,863 in 2025
The $1,863 reported for 2025 was more than what 89% of Nephrology (Internal Medicine) providers received nationally (typical 2025 total: $311).
See the full distribution for Nephrology (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,236 · 2020: $494 · 2021: $1,112 · 2022: $1,731 · 2023: $1,640 · 2024: $2,775 · 2025: $1,863.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,132 · Education: $146.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,132.11 |
| Education | $146.18 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $2,217.35 | 2019-2025 | Farxiga, Lokelma |
| Calliditas Therapeutics US INC. | $690.23 | 2022-2025 | Tarpeyo |
| Amgen INC. | $686.92 | 2019-2025 | Tavneos, Krystexxa, Aranesp |
| Bayer Healthcare Pharmaceuticals INC. | $628.95 | 2021-2025 | |
| Veloxis Pharmaceuticals, INC. | $602.06 | 2019-2025 | Envarsus |
| Otsuka America Pharmaceutical, INC. | $493.63 | 2019-2025 | Jynarque, Voyxact |
| Lilly USA, LLC | $491.70 | 2023-2025 | Jardiance, Mounjaro |
| Opko Pharmaceuticals, LLC | $485.90 | 2019-2025 | Rayaldee |
| Novartis Pharmaceuticals Corporation | $430.75 | 2019-2025 | |
| Mallinckrodt Hospital Products INC. | $429.73 | 2020-2025 | Acthar, Terlivaz |
| Horizon Therapeutics Plc | $365.32 | 2019-2023 | Krystexxa |
| Akebia Therapeutics INC | $357.54 | 2019-2024 | Vafseo, Auryxia |
| Travere Therapeutics, INC. | $288.91 | 2019-2025 | |
| Novo Nordisk INC | $287.34 | 2023-2025 | Ozempic, Rybelsus, Wegovy |
| Fresenius USA Marketing, INC. | $281.31 | 2019-2025 | Crit-Line, Velphoro |
Show all 44 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Cormedix INC. | $273.03 | 2024 | Defencath |
| Daiichi Sankyo INC. | $225.51 | 2019-2024 | Injectafer |
| Aurinia Pharma U.S., INC. | $216.67 | 2021-2023 | Lupkynis |
| Vifor Pharma, INC. | $195.03 | 2019-2023 | Veltassa, Korsuva |
| Glaxosmithkline, LLC. | $169.35 | 2021-2025 | Benlysta, Jesduvroq, Shingrix |
| Janssen Pharmaceuticals, INC | $143.58 | 2019-2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $125.77 | 2023-2025 | Jardiance, Tradjenta |
| Alexion Pharmaceuticals, INC. | $100.25 | 2021-2025 | Ultomiris |
| Arbor Pharmaceuticals, INC. | $59.29 | 2019-2020 | |
| Ani Pharmaceuticals, INC. | $54.99 | 2024-2025 | Purified Cortrophin Gel |
| Kyowa Kirin, INC. | $52.86 | 2023 | Crysvita |
| Mallinckrodt Enterprises LLC | $46.76 | 2019 | |
| Takeda Pharmaceuticals U.S.A., INC. | $46.59 | 2022 | |
| Ultragenyx Pharmaceutical INC. | $43.38 | 2019-2022 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $41.43 | 2023-2024 | Xifaxan |
| Ardelyx, INC. | $40.68 | 2024 | Ibsrela |
| Boston Scientific Corporation | $34.08 | 2023-2024 | Lux-Dx Insertable Cardiac Monitor, Ingevity+ |
| Pharmacosmos Therapeutics INC. | $28.70 | 2021 | |
| Nxstage Medical, INC. | $26.69 | 2022 | |
| Alnylam Pharmaceuticals INC. | $25.05 | 2024 | Onpattro |
| Nevro Corp. | $22.85 | 2023 | Senza |
| Pfizer INC. | $22.47 | 2025 | |
| Allergan, INC. | $21.44 | 2019 | |
| Xeris Pharmaceuticals, INC. | $19.15 | 2025 | Keveyis |
| Scpharmaceuticals INC. | $18.25 | 2025 | |
| Merck Sharp & Dohme LLC | $18.07 | 2023 | Verquvo |
| Renalytix Ai, INC. | $15.31 | 2022 | |
| Chiesi USA, INC. | $13.88 | 2025 | Elfabrio |
| Janssen Biotech, INC. | $12.76 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Melissa Isbell listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.